Private Equity

Amid a $2.37B buyout, Weiss Asset Management's increased stake in Avadel Pharma raises questions. Is it a vote of confidence or a strategic power play?

Greenway Technologies is leaving the lab. A new deal with a Native-owned firm aims to turn stranded gas into gold, but can the micro-plant economics work?

Hedge fund Balyasny Asset Management builds a 1.72% stake in JTC plc, signaling high-stakes maneuvering in the £2.3 billion takeover saga.

Boston's Weiss Asset Management reveals a strategic 4.17% derivative stake in International Personal Finance as a takeover deadline looms.

Nordic American Tankers is riding a wave of record profits, but the industry's future hinges on volatile markets and the shadow of Venezuelan oil.

A C$1M private placement for CHAR Technologies signals strong investor faith in its waste-to-energy tech, promising to decarbonize heavy industry.

With a $157M expansion, Hyosung aims to build the USA's largest transformer plant, tackling an energy crisis fueled by AI and an aging infrastructure.

A new car wash opening reveals a blueprint for modern industry disruption, blending aggressive growth, tech-driven efficiency, and savvy community strategy.

A junior miner is fast-tracking gold and critical metals production in Québec by reviving a key mill. Is this a strategic supply chain win or just savvy promotion?

Sintana Energy's all-share acquisition of Challenger gets final approval, creating a new exploration leader with high-impact assets in Namibia and Uruguay.

Aligos Therapeutics is using strategic stock grants to lure top talent. Is this a savvy growth play or a creeping cost for shareholders? We break it down.

Acadia's new powder form of the only Rett syndrome drug offers families vital choice, easing daily care and showing the power of patient-led innovation.

With full control of a prized Turkish zinc mine, Pasinex bets big on a 1,000-meter deep dig. Can this capital-intensive play pay off in a shifting market?

With its fourth acquisition under ZCG ownership, Unimed is consolidating the fragmented maritime health market, leveraging tech to create a dominant platform.

With over 123 million displaced, refugee camps are now de facto cities. Temporary water solutions are fueling disease, making the case for permanent fixes.

As Uxin prepares to report Q3 results, all eyes are on its ambitious superstore strategy and whether it can drive profitability in a complex market.

PSH continues its multi-billion dollar share repurchase strategy to tackle its stubborn stock discount. What does this mean for the fund and its future targets?

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.

Yum China's massive share buyback isn't just about rewarding investors. It's a calculated move signaling financial dominance in a complex market.

Centrus Energy is building a key Ohio facility, the first step in a multi-billion dollar plan to end US reliance on Russian uranium for next-gen reactors.